Vertex Pharmaceuticals (VRTX) — insider trading
Health Care · NASDAQ
Vertex Pharmaceuticals (VRTX) has 45 reported SEC Form 4 insider transactions in our data, including 15 open-market sales among the most recent 45 (latest 2026-09-08).
Recent Form 4 transactions
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-08 | van Grunsven Jasper | Officer (EVP, CP and NPPO) | Grant / award / vesting | 8,682 | — | $0 | Form 4 |
| 2026-08-28 | Ambrose Kristen | Officer (SVP & Chief Accounting Officer) | Grant / award / vesting | 5,000 | — | $0 | Form 4 |
| 2026-08-27 | SACHS BRUCE I | Director | Bona fide gift | 6,000 | — | $0 | Form 4 |
| 2026-07-21 | Sachdev Amit | Officer (EVP Chief Patient & Ext Af Off) | Grant / award / vesting | 8,251 | — | $0 | Form 4 |
| 2026-07-21 | Tatsis Ourania | Officer (EVP, Chief Reg. & Quality Off.) | Grant / award / vesting | 8,251 | — | $0 | Form 4 |
| 2026-07-15 | Garber Alan M | Director | Grant / award / vesting (derivative) | 32 | $475.28 | $15.0K | Form 4 |
| 2026-07-15 | SACHS BRUCE I | Director | Grant / award / vesting (derivative) | 100 | $475.28 | $47.5K | Form 4 |
| 2026-07-02 | McKechnie Duncan | Officer (EVP, Chief Commercial Officer) | Open-market sale | 1,541 | $519.00 | $799.8K | Form 4 |
| 2026-07-02 | Tatsis Ourania | Officer (EVP, Chief Reg. & Quality Off.) | Open-market sale | 1,500 | $524.99 | $787.5K | Form 4 |
| 2026-07-01 | Liu Joy | Officer (EVP and Chief Legal Officer) | Open-market sale | 828 | $502.71 | $416.2K | Form 4 |
| 2026-06-26 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 596 | $482.50 | $287.6K | Form 4 |
| 2026-06-18 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 1,020 | $462.17 | $471.4K | Form 4 |
| 2026-06-15 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 4,062 | $450.00 | $1.83M | Form 4 |
| 2026-06-05 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 1,745 | $450.00 | $785.3K | Form 4 |
| 2026-06-01 | Liu Joy | Officer (EVP and Chief Legal Officer) | Open-market sale | 828 | $439.91 | $364.2K | Form 4 |
| 2026-05-29 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 1,974 | $450.00 | $888.3K | Form 4 |
| 2026-05-15 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 1,354 | $453.45 | $614.0K | Form 4 |
| 2026-05-15 | Bunnage Mark E. | Officer (EVP, Chief Scientific Officer) | Open-market sale | 33 | $453.45 | $15.0K | Form 4 |
| 2026-05-12 | Bozic Carmen | Officer (EVP and CMO) | Open-market sale | 6,988 | $450.00 | $3.14M | Form 4 |
| 2026-05-04 | Bhatia Sangeeta N. | Director | Open-market sale | 318 | $423.73 | $134.7K | Form 4 |
| 2026-05-01 | Bhatia Sangeeta N. | Director | Grant / award / vesting | 943 | — | $0 | Form 4 |
| 2026-05-01 | CARNEY LLOYD | Director | Grant / award / vesting (derivative) | 2,866 | — | $0 | Form 4 |
| 2026-05-01 | Garber Alan M | Director | Grant / award / vesting (derivative) | 1,433 | — | $0 | Form 4 |
| 2026-05-01 | Garber Alan M | Director | Grant / award / vesting | 472 | — | $0 | Form 4 |
| 2026-05-01 | Lagarde Michel | Director | Grant / award / vesting (derivative) | 2,866 | — | $0 | Form 4 |
| 2026-05-01 | Liu Joy | Officer (EVP and Chief Legal Officer) | Open-market sale | 1,104 | $425.02 | $469.2K | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | Director | Grant / award / vesting (derivative) | 796 | — | — | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | Director | Disposition to the issuer | 796 | — | — | Form 4 |
| 2026-05-01 | MCKENZIE DIANA | Director | Grant / award / vesting | 943 | — | $0 | Form 4 |
| 2026-05-01 | SACHS BRUCE I | Director | Grant / award / vesting (derivative) | 2,866 | — | $0 | Form 4 |
| 2026-05-01 | Schneider Jennifer | Director | Grant / award / vesting (derivative) | 796 | — | — | Form 4 |
| 2026-05-01 | Schneider Jennifer | Director | Grant / award / vesting (derivative) | 1,433 | — | $0 | Form 4 |
| 2026-05-01 | Schneider Jennifer | Director | Disposition to the issuer | 796 | — | — | Form 4 |
| 2026-05-01 | Schneider Jennifer | Director | Grant / award / vesting | 472 | — | $0 | Form 4 |
| 2026-05-01 | Thornberry Nancy | Director | Grant / award / vesting (derivative) | 398 | — | — | Form 4 |
| 2026-05-01 | Thornberry Nancy | Director | Grant / award / vesting (derivative) | 1,433 | — | $0 | Form 4 |
| 2026-05-01 | Thornberry Nancy | Director | Disposition to the issuer | 398 | — | — | Form 4 |
| 2026-05-01 | Thornberry Nancy | Director | Grant / award / vesting | 472 | — | $0 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | Director | Grant / award / vesting (derivative) | 796 | — | — | Form 4 |
| 2026-05-01 | Upadhyay Suketu | Director | Grant / award / vesting (derivative) | 2,866 | — | $0 | Form 4 |
| 2026-05-01 | Upadhyay Suketu | Director | Disposition to the issuer | 796 | — | — | Form 4 |
| 2026-04-15 | Garber Alan M | Director | Grant / award / vesting (derivative) | 34 | $442.50 | $15.0K | Form 4 |
| 2026-04-15 | SACHS BRUCE I | Director | Grant / award / vesting (derivative) | 107 | $442.50 | $47.5K | Form 4 |
| 2026-04-15 | Upadhyay Suketu | Director | Grant / award / vesting (derivative) | 81 | $442.50 | $35.6K | Form 4 |
| 2026-04-01 | Liu Joy | Officer (EVP and Chief Legal Officer) | Open-market sale | 978 | $449.17 | $439.3K | Form 4 |
Ask the chat about VRTX's insider activity →
Transaction types are the SEC Form 4 codes: open-market purchases (P) and sales (S) are the only rows that reflect open-market conviction. Awards/vesting (A), option exercises (M/X/C), shares withheld for taxes (F) and gifts (G) are compensation or mechanical, not buying or selling on the open market. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan); open-market buying is not a recommendation to buy. Informational only — not financial advice.
Source: SEC EDGAR Form 3/4/5. See the full company profile: Vertex Pharmaceuticals (VRTX).
Last updated 2026-09-08 (most recent filing date).
Informational only — NOT financial advice. Insider filings are sourced from SEC EDGAR and shown with their reported dates.